OS7.3 Health-related quality of life (HRQoL) evaluation in the REGOMA trial: a randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

BACKGROUND: REGOMA trial showed that regorafenib (REG) significantly improved OS and PFS in patients (pts) with relapsed GBM with respect to lomustine (LOM). REG showed a different toxicity profile compared to LOM. Here, we report final results of the HRQoL assessment, a secondary end point. MATERIA...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Lombardi, G, Del Bianco, P, Brandes, A, Eoli, M, Rudà, R, Ibrahim, T, Lolli, I, Pace, A, Daniele, B, Pasqualetti, F, Rizzato, S, Bergo, E, Caccese, M, Padovan, M, Soffietti, R, De Salvo, G, Zagonel, V
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Oral Presentations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795122/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.046
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items